Circulation, Vol 71, 562-570, Copyright © 1985 by American Heart Association
RL Rothbard, PG Fitzpatrick, CW Francis, DM Caton, WB Hood Jr and VJ Marder
The influence of a systemic lytic state on reperfusion obtained after
intracoronary streptokinase (SK) therapy has been evaluated in 15 patients
with acute myocardial infarction and complete coronary occlusion. Coronary
angiographic studies and measurements of blood fibrinolytic parameters were
repeated at 15 min intervals during the infusion of a standard dose of SK
and were compared with the results with approximately one-tenth the
standard dose. Successful reperfusion was obtained in only 20% (2/10) of
patients receiving the low dose, compared with a 75% to 80% success rate in
patients receiving the standard dose as initial treatment (4/5) or as
follow-up treatment of patients in whom low-dose therapy failed (6/8).
There was a striking association between reperfusion and development of the
lytic state in that all 12 treatments resulting in reperfusion also caused
a lytic state and all seven treatments that failed to produce a lytic state
also failed to induce reperfusion (p less than .001). Among the
successfully treated patients, the dose of SK that induced a lytic state
was relatively constant. However, coronary arterial thrombi differed in
susceptibility to treatment. Sensitive thrombi (5/12) dissolved before the
lytic state occurred and at a lower SK dose than that needed to cause a
lytic state; more resistant thrombi (7/12) required a longer time and a
significantly larger SK dose to dissolve. These results indicate that
intrinsic properties of the thrombus influence the rate and outcome of
treatment and that a minimal dose of SK (about 200,000 U) is required to
ensure lasting reperfusion in susceptible patients.(ABSTRACT TRUNCATED AT
250 WORDS)
ARTICLES
Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase
This article has been cited by other articles:
![]() |
J. H. Sobel, I. Trakht, N. Pileggi, and H. Qi Wu Antipeptide Monoclonal Antibodies to Defined Fibrinogen Aalpha Chain Regions: Anti-Aalpha 487-498, a Structural Probe for Fibrinogenolysis Blood, March 1, 1998; 91(5): 1590 - 1598. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chouhan, H. A. Hajar, T. George, and J. C. Pomposiello Clinical and Angiographic Features of Patients with an Occluded Versus a Patent Infarct Vessel After Intravenous Streptokinase for Acute Myocardial Infarction Angiology, June 1, 1993; 44(6): 425 - 431. [Abstract] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1985 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |